A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer.

Matthew John Roberts Nathan Papa Marlon Lakmal Perera Susan ScottPatrick E TelokenAndre JoshiIan Vela David I Pryor Jarad Martin Henry H Woo

Published in: BJU international (2019)

National claims data indicate there has been a reduction in PCa treatment since 2009, which is mostly attributable to a reduction in the treatment of younger patients and reduced use of brachytherapy. RP is most commonly used and its use is rising in men aged >65 years.

Keyphrases

prostate cancer
end stage renal disease
radiation therapy
chronic kidney disease
early stage
high dose
newly diagnosed
ejection fraction
radical prostatectomy
peritoneal dialysis
low dose
machine learning
big data
replacement therapy
patient reported